Skip N2 Metastasis in Pulmonary Adenocarcinoma: Good Prognosis Similar to N1 Disease

被引:13
|
作者
Wang, Lin [1 ]
Ye, Guanzhi [1 ]
Xue, Liang [1 ]
Zhan, Cheng [1 ]
Gu, Jie [1 ]
Xi, Junjie [1 ]
Lin, Zongwu [1 ]
Jiang, Wei [1 ]
Ge, Di [1 ]
Wang, Qun [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
关键词
Lymph node metastasis; N1; disease; N2; Pathological subtype; pN sub-classification; RESPIRATORY SOCIETY CLASSIFICATION; LYMPH-NODE INVOLVEMENT; LUNG ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; IASLC/ATS/ERS CLASSIFICATION; CANCER; RECURRENCE; SURVIVAL; SUBTYPES; RESECTION;
D O I
10.1016/j.cllc.2020.02.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analyzed the prognosis of lung adenocarcinoma to elucidate the influence of skip N2 metastasis. Skip N2 disease has a similar prognosis to N1 disease and is significantly better than that of non-skip N2 disease. Skip N2 has a prognostic advantage in patients with the acinar-predominant subtype. Pathological subtypes of lung adenocarcinoma may influence subgroup of patients with lymph node metastasis. Introduction: The prognostic effect and mechanism of skip N2 lung cancer remain unclear. Our study aimed to elucidate the influence of skip N2 on overall survival (OS) and disease-free survival (DFS) compared with N1 and non-skip N2 in patients with lung adenocarcinoma. Patients and Methods: Patients with lung adenocarcinoma and lymph node involvement between May 2011 and December 2015 were retrospectively analyzed. The outcomes of skip N2 patients were compared with N1 and non-skip N2 patients. Prognosis was further investigated according to the N status in different adenocarcinoma subtypes. Univariate and multivariate analyses were carried out to define independent risk factors for OS and DFS. Results: A total of 456 patients with lung adenocarcinoma, 169 with N1 disease, 81 with skip N2 disease, and 206 with non-skip N2 disease, were enrolled in this study. All tumors were invasive adenocarcinoma, and the predominant subtypes were acinar in 252, papillary in 42, solid in 119, micropapillary in 20, and invasive mucinous adenocarcinoma in 23 patients. The DFS and OS of N1 and skip N2 diseases were similar and significantly better than those of patients with non-skip N2 disease. The prognosis according to lymph node status was significantly different in acinar-predominant subtypes in terms of both OS and DFS. Conclusions: Skip N2 disease has a similar prognosis to N1 disease and is significantly better than that of non-skip N2 disease in relation to OS and DFS. Skip N2 has a prognostic advantage in patients with the acinar-predominant subtype. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:E423 / E434
页数:12
相关论文
共 50 条
  • [1] Lung adenocarcinoma: Are skip N2 metastases different from non-skip?
    Li, Hang
    Hu, Hong
    Wang, Rui
    Li, Yuan
    Shen, Lei
    Sun, Yihua
    Chen, Haiquan
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 150 (04) : 790 - 795
  • [2] Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients With Stages II to III Lung Adenocarcinoma
    Li, Yan
    Byun, Alexander J.
    Choe, Jennie K.
    Lu, Shaohua
    Restle, David
    Eguchi, Takashi
    Tan, Kay See
    Saini, Jasmeen
    Huang, James
    Rocco, Gaetano
    Jones, David R.
    Travis, William D.
    Adusumilli, Prasad S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 608 - 619
  • [3] Assessment of Clinical Stage IA Lung Adenocarcinoma with pN1/N2 Metastasis Using CT Quantitative Texture Analysis
    Zhu, Haixu
    Xu, Yanyan
    Liang, Nanxue
    Sun, Hongliang
    Huang, Zhenguo
    Xie, Sheng
    Wang, Wu
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6421 - 6430
  • [4] Role of skip N2 lymph node metastasis for patients with the stage III-N2 lung adenocarcinoma: a propensity score matching analysis
    Wang, Shize
    Xie, Shaonan
    Han, Yaqing
    Gao, Maogang
    Su, Xin
    Liu, Qingyi
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [5] Skip metastasis and hidden N2 disease in lung cancer: How successful is mediastinal dissection?
    Tsubota, N
    Yoshimura, M
    SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1996, 26 (03): : 169 - 172
  • [6] Single-station skip-N2 disease: good prognosis in resected non-small-cell lung cancer (long-term results in skip-N2 disease)
    Yazgan, Serkan
    Ucvet, Ahmet
    Gursoy, Soner
    Samancilar, Ozgur
    Yagci, Tarik
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2019, 28 (02) : 247 - 252
  • [7] Prognosis and Clinicopathologic Characteristics of Skip N2 Metastasis in Completely Resected Non-Small Cell Lung Cancer
    Tsuboi, T.
    Eriguchi, D.
    Nemoto, D.
    Samejima, J.
    Nagashima, T.
    Ito, H.
    Nakayama, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S551 - S551
  • [8] Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma
    Chen, Qiangda
    Yin, Hanlin
    Liu, Siyao
    Shoucair, Sami
    Ding, Ni
    Ji, Yuan
    Zhang, Jicheng
    Wang, Dansong
    Kuang, Tiantao
    Xu, Xuefeng
    Yu, Jun
    Wu, Wenchuan
    Pu, Ning
    Lou, Wenhui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (12)
  • [9] The Significance of Skip Mediastinal Lymph Node Metastasis in the Prognosis of Patients with Resected Non-Small-Cell Lung Carcinoma: Is It Really a Better N2 Disease Subtype?
    Seyrek, Yunus
    Cansever, Levent
    Metin, Muzaffer
    Bolat, Erkut
    Bedirhan, Mehmet Ali
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 27 (05) : 304 - 310
  • [10] Prognosis of upstaged N1 and N2 disease after curative resection in patients with clinical N0 non-small cell lung cancer
    Park, Jae Kil
    Moon, Youngkyu
    JOURNAL OF THORACIC DISEASE, 2019, 11 (04) : 1202 - 1212